Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

It's one of many changes Bayer CEO Bill Anderson has made. Still, the company's stock price this year has struggled.

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

Notably, the company warned that 2025 will be weaker ... Sales of glyphosate-based herbicides declined by 19% YoY. Meanwhile, Bayer's Pharmaceutical division has delivered mixed performance.